Metrics as of 10/15/2026, 11:45 PM (Berlin time), refresh in progress.
Charles River Laboratories International Stock
Charles River Laboratories International, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Birgit Girshick
- Employees
- 19,000
- Market cap
- $14.5 B
- IPO
- 23/06/2000
Charles River Laboratories International, Inc. operates as a contract research organization within the healthcare sector, providing essential preclinical services to the pharmaceutical and biotechnology industries. Founded in 1947, the company is headquartered in Wilmington. Its core business revolves around assisting…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Charles River Laboratories International stock: price history
1D
-2.0%
1W
-0.5%
1M
+9.8%
6M
+63.2%
YTD
+50.5%
1Y
+71.6%
2Y
+53.8%
5Y
-25.6%
10Y
+270.2%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~72% stronger price swings than usual
Charles River Laboratories International stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Charles River Laboratories operates as a Contract Research Organization providing specialized services to the pharmaceutical and biotechnology industries. The business model is divided into the segments Discovery and Safety Assessment, Research Models and Services, and Manufacturing Solutions. The focus areas include supporting early drug development through safety testing such as toxicology and pharmacokinetics, providing specialized research models from rodents, and quality control for sterile and non-sterile pharmaceutical products. The company supports customers across all phases from the identification of therapeutic targets through manufacturing safety and also offers solutions for the management of animal facility operations.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Weak
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Charles River Laboratories International
Analyst assessment of Charles River Laboratories International
PRICE TARGET LOW
US$219.00
CONSENSUS
US$308.36
MEDIAN
US$326.00
PRICE TARGET HIGH
US$357.00
1
STRONG BUY
26
BUY
10
HOLD
0
SELL
0
STRONG SELL
37
TOTAL · Buy
As of: 13/10/2026
Charles River Laboratories International stock metrics
P/E
-62.01
P/B
5.12
EV/EBITDA
78.44
RETURN ON EQUITY
-0.1%
NET MARGIN
-0.1%
DEBT/EQUITY
1.07
DIVIDEND YIELD
0.0%
AS OF
27/06/2026
Free float & liquidity
FREE FLOAT
98.0%
FLOAT SHARES
47,204,893
AVG. DAILY VOLUME (30D)
979,291
Insider transactions (SEC)
Parisotto Shannon M
Parisotto Shannon M
Coleman Glenn
FOSTER JAMES C
FOSTER JAMES C
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.0%
Forums (Reddit)
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Charles River Laboratories International stock
What does Charles River Laboratories International do?
Charles River Laboratories International, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Birgit Girshick, the company employs around 19,000 people.
The IPO was on 23/06/2000; the stock trades on NYSE under the ticker CRL.
What do analysts say about Charles River Laboratories International stock?
37 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$308.36, ranging from US$219.00 to US$357.00, with a median of US$326.00.
This is an external assessment, not a statement by Market Jury.
When does Charles River Laboratories International report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 72% stronger than usual.
Does Charles River Laboratories International pay a dividend?
No, Charles River Laboratories International currently does not pay a dividend.
Which stocks are comparable to Charles River Laboratories International?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Charles River Laboratories International stock analyzed?
Clicking "Analyze stock" lets five strategies assess Charles River Laboratories International against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.